Compare ARQT & PRVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARQT | PRVA |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 2020 | 2021 |
| Metric | ARQT | PRVA |
|---|---|---|
| Price | $27.83 | $24.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $34.00 | $31.17 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.79 | 63.64 |
| EPS | N/A | ★ 0.02 |
| Revenue | $376,072,000.00 | ★ $2,122,842,000.00 |
| Revenue This Year | $34.85 | $18.19 |
| Revenue Next Year | $29.39 | $10.72 |
| P/E Ratio | ★ N/A | $1,233.50 |
| Revenue Growth | ★ 91.34 | 22.26 |
| 52 Week Low | $13.70 | $18.78 |
| 52 Week High | $31.77 | $28.82 |
| Indicator | ARQT | PRVA |
|---|---|---|
| Relative Strength Index (RSI) | 57.42 | 41.23 |
| Support Level | $27.63 | $22.78 |
| Resistance Level | $29.47 | $26.50 |
| Average True Range (ATR) | 1.17 | 0.96 |
| MACD | -0.16 | -0.45 |
| Stochastic Oscillator | 48.17 | 11.10 |
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.